Barbara Sosnowski is Vice President and ES&I Head, Cambridge Research Units. Barbara has had multiple expanding roles within Pfizer since her arrival to Pfizer 8 years ago. She is currently Vice President and External Science & innovation (ES&I) Head, Cambridge Research Units; Global Head, WRD External Partnerships, Worldwide Research & Development. This role oversees identifiying external opportunities from discovery to Phase 2b in the areas of Inflammation and Immunology, Cardiovascular, Neuro-inflammation, Rare Disease, Gene Therapy, Genonme Science and Technology, Platform technologies and Vaccine R&D. Barbara oversees a group of scientists that are experts in each of these areas. Prior to joining Pfizer Barbara was Vice President, Biologics Development of Cardium Therapeutics and was appointed Chief Operating Officer of Tissue Repair Company following Cardium’s acquisition of Tissue Repair Company in August 2006. Prior to the acquisition, Dr. Sosnowski served as President and CEO of Tissue Repair Company. Dr. Sosnowski has more than 25 years in the health care industry. From June 2001 to December 2004 she served as Vice President Research and Development of Selective Genetics Inc. a tissue repair company that developed wound repair, orthopedic and cardiovascular products. At Selective Genetics, she co-invented and helped develop the targeted gene therapy program, both viral and non-viral. Prior to Selective Genetics she was employed by Prizm Pharmaceuticals from October 1992. Prior to joining Prizm, Dr. Sosnowski was at Ligand Pharmaceuticals, where her efforts were focused on identification of small molecule inhibitors of osteoporosis. Dr. Sosnowski received her BA in Biological Sciences from the University of California, Berkeley and PhD in Biological Sciences from Johns Hopkins University. She is also a registered patent agent.